Affiliation:
1. Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani, Pilani Campus, Rajasthan 333031, India
2. Birla Institute of Technology and Science (BITS), Pilani, Dubai Campus, UAE
Abstract
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that is characterized by synovial inflammation, cellular infiltration in joints which leads to progressive joint destruction and bone erosion. RA is associated with many comorbidities including pulmonary disease, rheumatoid nodules and can have a pessimistic impact on quality of life. The current therapies of RA treatment comprise conventional, small molecule and biological antirheumatic drugs. Their utility as therapeutic agents is limited because of poor absorption, rapid metabolism and adverse effects (dose-escalation, systemic toxicity, lack of selectivity and safety). To overcome these limitations, the novel drug delivery systems are being investigated. This review has compiled currently approved therapies along with emerging advanced drug-delivery systems for RA treatment. Further, active targeting of therapeutic agents to inflamed joints via folate receptor, CD44, angiogenesis, integrins and other provided an improved therapeutic efficacy in the treatment of RA.
Reference133 articles.
1. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
2. Global RA Network. About Arthritis and RA. https://globalranetwork.org/project/disease-info/
3. India. Arthritis. www.arthritis-india.com/rheumatoid-arthritis.html
4. WHO. Chronic rheumatic conditions. www.who.int/chp/topics/rheumatic/en/
5. The Pathogenesis of Rheumatoid Arthritis
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献